This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Spectranetics Announces U.S. Launch Of The TAPAS(TM) Catheter And Preclinical Animal Data On Drug Uptake In Peripheral Vessels

Stocks in this article: SPNC

COLORADO SPRINGS, Colo., Oct. 8, 2012 (GLOBE NEWSWIRE) -- Consistent with its commitment to eradicating restenosis and amputations, Spectranetics Corporation (Nasdaq:SPNC) today announced the U.S. market launch of the TAPAS catheter at the 2012 Vascular Interventional Advances (VIVA) conference in Las Vegas. TAPAS is manufactured by ThermopeutiX, Inc. and distributed by Spectranetics. In conjunction with the launch at VIVA, Dr. Mehdi Shishehbor, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH will present his study results  on preclinical animal data at VIVA Continuing Medical Education event titled "Contemporary Options for Complex Lower Extremity Disease." This CME event is supported by an unrestricted educational grant from Spectranetics. The purpose of the study was to evaluate the uptake of a drug delivered intra-arterially via the TAPAS™ Catheter in a swine model.

The TAPAS catheter is the first drug infusion system to provide a versatile solution using a single adjustable and repositionable catheter to deliver any physician-specified drug or diagnostic agent. Its dual occlusion balloon design allows for precise targeting of the treatment area, delivery and dwell time of the drug, and aspiration to minimize systemic effects.

"The addition of TAPAS to our portfolio reflects our recognition of the clinical need for localized drug therapy within peripheral arteries," said Jason Hein, Senior Vice President and General Manager of Vascular Intervention at Spectranetics. "This is an exciting opportunity for physicians to provide an adjunctive therapy to their patients whose recurrent disease has not been successfully managed with existing treatment options."

Dr. Rich Kovach, Chief of Interventional Cardiology, Deborah Heart and Lung Center, stated, "I have found the TAPAS catheter to be very easy to use and the versatility is quite appealing. The adjustability of the device allows lesions from 15mm to 300mm to be treated with one device, and it can be used to treat multiple lesions within a single vessel. The device also allows the physician to choose the agent that would best serve the patient's clinical presentation. Using a device with such versatility also provides potential for significant economic benefit over other technologies, which can only be used once in the same patient, and need to be stocked in multiple sizes."

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs